519 related articles for article (PubMed ID: 24375052)
1. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet MH; Smits MM; Morsink LM; Diamant M
Nat Rev Nephrol; 2014 Feb; 10(2):88-103. PubMed ID: 24375052
[TBL] [Abstract][Full Text] [Related]
2. Renoprotection in diabetic kidney disease: can incretin-based therapies deliver?
van Baar MJB; van Raalte DH
Curr Opin Nephrol Hypertens; 2020 Jan; 29(1):103-111. PubMed ID: 31714285
[TBL] [Abstract][Full Text] [Related]
3. Physiology and pathophysiology of incretins in the kidney.
von Websky K; Reichetzeder C; Hocher B
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
[TBL] [Abstract][Full Text] [Related]
4. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
Muskiet MHA; Tonneijck L; Smits MM; van Baar MJB; Kramer MHH; Hoorn EJ; Joles JA; van Raalte DH
Nat Rev Nephrol; 2017 Oct; 13(10):605-628. PubMed ID: 28869249
[TBL] [Abstract][Full Text] [Related]
5. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus.
Campbell RK
Clin Ther; 2011 May; 33(5):511-27. PubMed ID: 21665040
[TBL] [Abstract][Full Text] [Related]
6. Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes.
van Genugten RE; Möller-Goede DL; van Raalte DH; Diamant M
Diabetes Obes Metab; 2013 Jul; 15(7):593-606. PubMed ID: 23216746
[TBL] [Abstract][Full Text] [Related]
7. Diabetic nephropathy: new approaches for improving glycemic control and reducing risk.
Schernthaner G; Schernthaner GH
J Nephrol; 2013; 26(6):975-85. PubMed ID: 23807645
[TBL] [Abstract][Full Text] [Related]
8. Review of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects.
Sloan LA
J Diabetes; 2019 Dec; 11(12):938-948. PubMed ID: 31318152
[TBL] [Abstract][Full Text] [Related]
9. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Nauck M
Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
[TBL] [Abstract][Full Text] [Related]
10. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
11. Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence.
Alicic RZ; Cox EJ; Neumiller JJ; Tuttle KR
Nat Rev Nephrol; 2021 Apr; 17(4):227-244. PubMed ID: 33219281
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
[TBL] [Abstract][Full Text] [Related]
13. The potential for renoprotection with incretin-based drugs.
Tanaka T; Higashijima Y; Wada T; Nangaku M
Kidney Int; 2014 Oct; 86(4):701-11. PubMed ID: 25007170
[TBL] [Abstract][Full Text] [Related]
14. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
15. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
Panchapakesan U; Mather A; Pollock C
Clin Sci (Lond); 2013 Jan; 124(1):17-26. PubMed ID: 22963445
[TBL] [Abstract][Full Text] [Related]
16. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
17. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
Dejager S; Schweizer A
Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
[TBL] [Abstract][Full Text] [Related]
18. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
Yamagishi S; Matsui T
Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
[TBL] [Abstract][Full Text] [Related]
19. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
20. Effects of Diabetes Medications Targeting the Incretin System on the Kidney.
MacIsaac RJ; Thomas MC
Clin J Am Soc Nephrol; 2018 Feb; 13(2):321-323. PubMed ID: 29321176
[No Abstract] [Full Text] [Related]
[Next] [New Search]
